• The COVID-19 pandemic has accelerated development of innovative mRNA-based therapies
  • Evonik expands its position as integrated solutions provider
  • Above-average growth potential for the Health Care business

Please find the presentation in the download area on the right side!

Attachments

  • Original document
  • Permalink

Disclaimer

Evonik Industries AG published this content on 07 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 December 2020 05:59:06 UTC